About Prevencio, Inc.
Prevencio’s value proposition is “Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, coronary artery calcium scores, single protein tests, and multi-protein tests. The company is headquartered in Kirkland, Washington. For additional information, visit www.PrevencioMed.com.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need and size, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.